none

PAIN MEDS BEFORE THE ACCC AGAIN

07-12-2017
by 
in 

Just one year ago pain med brand Nurofen was slugged with a $6 million dollar fine for making false claims about pain relief; now Voltaren is under fire for the exact same issue.

The ACCC has filed formal proceedings in the Federal Court against GlaxoSmithKline and Novartis, alleging the drugmakers misled consumers in the marketing of Voltaren Emulgel and Osteo Gel pain relief products.

Osteo Gel is marketed as being formulated for treating osteoarthritis conditions, but both Voltaren and Osteo Gel contain the same active ingredient: diclofenac diethylammonium gel 11.6mg/g.

While the recommended retail price of Osteo Gel 150 is $3 more expensive than Emulgel 150g at $28.99 compared with $25.99, the ACCC said the former was found in-store at a mark-up of up to $7.50, or 33 per cent.

“We’re so disappointed that having taken the Nurofen case, with all of the publicity around it, that we find this sort of behaviour still continuing,” Mr Sims said. 

Mr Sims said if the ACCC won the case, the watchdog would be seeking an even higher penalty than against Nurofen. “If we’re successful, we’d be looking at trying to get an even stronger deterrence message out there” he said.

Mr Sims said the ACCC was also concerned that the products were targeted at older consumers. “We’re always concerned with conduct that affects consumers who could be seen as slightly more vulnerable,” he said.

“What was happening here is that they were saying you’ve got a product that is specifically formulated for treating osteoarthritis, particularly in the knees and fingers, and indeed saying that also it’s more effective than Emulgel.

“Our concerns were not only that consumers were paying more for Osteo Gel, but they could actually buy both products and have them in their medical cabinet, thinking they treat different things.”

GSK acquired the Voltaren brand from Novartis in 2016 but the products have been sold since 2010. In March this year, GSK amended the Osteo Gel packaging to include the statement, “Same effective formula as Voltaren Emulgel”, but the ACCC alleges the amended packaging is also likely to be misleading.

Related news & editorials

  1. With the new year shifting into gear, Australian manufacturing is following suit, with increased expansion on the back of the construction industry.
    02.03.2021
    02.03.2021
    by      In , In
    With the new year shifting into gear, Australian manufacturing is following suit, with increased expansion on the back of the construction industry.
    The Australian Industry Group’s Performance of Manufacturing Index has increased by 3.5 points to 58.8 in February with the stronger pace of recovery... Read More
  2. The waste will be transported through a combination of conveyors, pallets (including 908 individual pallet locations), racking, and Swisslog’s S12 Vectura crane.
    02.03.2021
    02.03.2021
    by      In , In
    Nuclear waste is extremely dangerous when mishandled and can lead to untold human and environmental damages.
    That’s why Australia’s Nuclear Science and Technology Organisation (ANSTO), which produces nuclear medicine vital to the Australian health industry, turned to Swisslog’s automated storage... Read More
  3. When PMFV is applied through two stage technology models it can provide up to 50% increased efficiency over conventional compressor types.
    24.02.2021
    24.02.2021
    by      In , In
    The restrictions that COVID-19 placed on us from 2020,  is a wake up call on export and import reliance for many industries. 
    We can continue as we were and hope for a slow progress to recovery or learn some important lessons in adaptability to the current and future business environment with... Read More
  4. Scott Philbrook, ANZ Managing Director, RS Components
    24.02.2021
    24.02.2021
    by      In , In , In
    Covid-19 seriously disrupted supply chains throughout industry worldwide. Scott Philbrook, Managing Director RS Components Australia, explains today’s necessity for supply chain resilience and continuity.
    The Institute of Supply Management reported that in March, at the start of the pandemic, 75%... Read More
Products
Suppliers